15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Mink Therapeutics Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $35.00 to $35.00, so the covering firms are broadly aligned. The average target of $35.00 sits 201% above the current $11.62. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.39 next quarter toward $-2.65 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Mink Therapeutics Inc.
As of Sep, 1 of 1 firms rate INKT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
INKT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.39
Range $-0.39 – $-0.39 · 1 analysts · -30% YoY
Next period, 1 analysts expect Mink Therapeutics Inc to earn $-0.39 a share (range $-0.39 – $-0.39), versus $-0.56 a year earlier. Full-year consensus is $-1.93, growing to $-2.65 the year after.
REVENUE · NEXT QUARTER
$1.8M
Range $1.8M – $1.8M · 1 analysts
Revenue is expected to reach $1.8M (range $1.8M – $1.8M). Full-year consensus is $3.4M, rising to $2.0M next year.
Top analysts covering Mink Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INKT.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$43.00+270.2% to target
Overall win rate
50%
+ Follow
#2
Emily Bodnar
HC Wainwright & Co. · Rank #399
Buy
$35.00+201.3% to target
Overall win rate
23%
+ Follow
#3
MP
Matt Phipps
William Blair
Hold
No targeton INKT
Coverage
—
+ Follow
#4
JA
Jack Allen
Baird
Buy
$4.00-65.6% to target
Coverage
—
+ Follow
INKT stock forecast FAQ
What is INKT's average 12-month price target?+
The 1 analysts with a live target average $35.00 for Mink Therapeutics Inc over the next 12 months, ranging from a $35.00 high to a $35.00 low.
Is INKT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover INKT?+
1 analysts have an active rating on Mink Therapeutics Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering INKT?+
Among analysts who currently cover INKT, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $43.00 target.
What is Mink Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.39 per share (range $-0.39 – $-0.39) across 1 analysts. Full-year EPS is projected at $-1.93, rising to $-2.65 the following year.
How much revenue is Mink Therapeutics Inc expected to report next quarter?+
Consensus revenue is $1.8M (range $1.8M – $1.8M). Full-year revenue is projected at $3.4M, growing to $2.0M next year.
Have analysts been upgrading or downgrading INKT lately?+
As of Sep, 1 of 1 firms rate INKT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INKT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
